Investors

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Start Investors Equity Issues Rights Issue 2020

Rights Issue 2020

Prospectus rights issue, Nov 5 2020 (in Swedish)

Supplement to prospectus regarding rights issue (in Swedish) Nov 12 2020

Prospectus for admission to trading on Nasdaq Stockholm (.pdf, in Swedish)

For Annual Reports of the acquired company Rare Thyroid Therapeutics, please refer to corresponding page in Swedish.

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]